Agenda

Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.

Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.

In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.

This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.

Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them
The audience can expect to be able to participate actively in the “conversation” and contribute to the program

* Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
* Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
* Understand Gx / biosimilar product development and entry strategies
* Identify potential actions to optimize launches

In 2014 Dig Worldwide developed and introduced COGIntel a quick, robust and cost effective COGs benchmarking solution.
Technical Cost Modelling (TCM) , a method developed at MIT in the 1980’s has long been the gold standard in benchmarking cost-of-goods sold which is time and resource intensive with a limited shelf-life. Although not as precise as TCM, Dig Worldwide’s bespoke COGIntel method allows rapid and cost effective COG benchmarking analysis that provides “good enough” competitive intelligence for strategic decision making. Performance gaps and areas of advantage or disadvantage become visible verses forgotten.
An illustrative CAR-T case study will form an integral part of the talk to help illustrate Dig Worldwide’s methodology.

From target identification and drug development to patient diagnosis and even to patient care, CI professionals need to be able to keep up with the increasing pace of business and ever-expanding competitive landscape. Through advancements in research, CI professionals can better understand the vast amount of patient, research, and diagnostic data to make better investment decisions.

Join this session to learn:
• How to leverage the building blocks of Natural Language Processing and Machine learning to drive forward offerings in Sentiment Analysis, thematic and KPI extraction, and enterprise knowledge management
• How these technologies are already impacting the pharma professional’s day-to-day
• How advancements in AI will impact the pharma industry long term and may reshape the duties of a Competitive Intelligence team

1. Evaluating physicians brand perception, usage, adoption of a recently launched product
2. Analyzing patient brand usage, social media listening for efficacy, side effects & cost

Strategic use of real-time intelligence helps decision-makers in 4 ways:
1. Evaluate target product profiles (TPP) for approved and upcoming treatment options
2. Assess unmet medical needs, time to diagnose, treatment journey and treatment switch
3. Analyse patient sentiments for targeted brand versus competitive brands
4. Visualization of unmet medical needs, prescription drivers for target brand and in-depth intelligence on competitors’ brand